Takeda out-licenses Japan rights to relugolix in women's health indications
Takeda Pharmaceutical (TYO: 4502) has entered into a licensing agreement to grant fellow Japanese drugmaker ASKA Pharmaceutical exclusive commercialization right for uterine fibroids and exclusive development and commercialization rights for endometriosis for Japan to maximize the product value of Takeda-owned relugolix (development code: TAK-385).
Takeda’s shares edged up 1.55% to 4,452 yen following the announcement this morning.
Relugolix is being developed as a gonadotropin-releasing receptor antagonist to be taken orally, once daily against uterine fibroids, endometriosis and prostate cancer.
Positive top-line results were reported from a Phase III trial of relugolix for the treatment of pain associated with uterine fibroids last November. Relugolix met the primary endpoint of Takeda's trial, with 57.6% of women achieving marked improvement in pain symptoms compared to 3.1% of women receiving placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze